To study the efficacy and safety of ormeloxifene in the medical management of AUB.
Methods: 50 women with HMB who satisfied inclusion criteria were included in the study. Ormeloxifene 60 mg tablet twice a week for the first 12 weeks and then once a week for 12 weeks was given for every patient. The outcome was assessed by assessment of menstrual blood flow by PBAC score, Hb level and endometrial thickness
Results: The PBAC score was significantly reduced in 85 % of patients. The mean Hb concentration was significantly increased from 8.6 to 11.8 g/dl. The mean endometrial thickness was reduced from 10.14 mm to 7.35 mm
Conclusion: Ormeloxifene is an effective and user friendly drug for medical management of AUB.